← Leaderboards
Thomas Blue
Friends Research Institute, Inc.
$3,451,199
Attributed
$6,902,397
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.3M · FY2023–25$5M$3.8M$2.5M$1.3M$0
'23
'24
'25
Funding mix
By agency
NIH$6,902,397 · 3
By mechanism
R01$3,097,234 · 1
UG1$2,411,241 · 1
UM1$1,393,922 · 1
Top collaborators
- Michael Scott Gordon6 shared
Most similar at Friends Research Institute, Inc.
Same institution · by research overlap
- Michael Scott Gordon$19,460,241
- Jan Gryczynski$15,962,910
- Steven Bernard Carswell$4,215,696
- Karli Rae Hochstatter$3,132,462
- Timothy W Kinlock$10,085,018
Others in their field
Other Rising Stars on “Injections”
- Supriya Menezes · The Emmes Company, Llc$18,394,958
- Debra Burnin · Sri International$6,761,472
- Andrew Gardiner · Libero Pharma Limited$6,351,015
- Sabrina Paganoni · Massachusetts General Hospital$6,045,501
- Suma Babu · Massachusetts General Hospital$6,045,501
- Mark Sorenson · Nirsum Laboratories, Inc.$4,866,388
Research focus
InjectionsOverdose DeathPublic HealthUrineRisk BehaviorsRearrestOpioidPharmaceutical PreparationsReincarcerationSafetyInnovationInjectableHiv RiskCommunitiesImprisonmentNeedlesOpioid UseCostAccidentsCrimeAdministratorContinuity Of Patient CareFundingFormulation
Grant awards (6)
A patient preference trial of sublingual versus extended-release buprenorphine telemedicine and pharmacy linkage for individuals re-entering the community from jail$1,393,922
UM1 · FY2025 · DA · contact PI
A comparative effectiveness trial of sublingual versus extended-release buprenorphine with individuals leaving a carceral setting$1,129,361
R01 · FY2025 · DA
A comparative effectiveness trial of sublingual versus extended-release buprenorphine with individuals leaving a carceral setting$1,086,043
R01 · FY2024 · DA
A comparative effectiveness trial of extended release naltrexone versus extended-release buprenorphine with individuals leaving jail$1,967,149
UG1 · FY2023 · DA
A comparative effectiveness trial of sublingual versus extended-release buprenorphine with individuals leaving a carceral setting$881,830
R01 · FY2023 · DA
Long-acting naltrexone for pre-release prisoners: A randomized trial of mobile treatment$444,092
UG1 · FY2023 · DA